SCHEMBL8554106

SCHEMBL8554106

Cc1nc(-c2cc(C)c(O)c(C)c2)no1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
PLK1 P53350 1/20 0.46
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
LMNA P02545 3/20 0.42
RAB9A P51151 3/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
MAPK14 Q16539 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
HTT P42858 2/20 0.39
HPGD P15428 1/20 0.39
NPC1 O15118 2/20 0.39
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8977892 0.90 L3MBTL1 (0.50) L3MBTL1CA1CA2PLK1CA12
SCHEMBL18471229 0.84 L3MBTL1 (0.60) L3MBTL1CA1CA2PLK1CA12
SCHEMBL15261955 0.81 L3MBTL1 (0.56) L3MBTL1CA1CA2PLK1CA12
SCHEMBL8663061 0.81 L3MBTL1 (0.56) L3MBTL1CA1CA2PLK1CA12
SCHEMBL18518446 0.81 L3MBTL1 (0.56) L3MBTL1CA1CA2PLK1CA12
SCHEMBL12947695 0.80 L3MBTL1 (0.61) L3MBTL1CA1CA2PLK1CA12
SCHEMBL9179130 0.79 PTGS1 (0.59) L3MBTL1CA1CA2SMN1; SMN2
SCHEMBL6935323 0.79 L3MBTL1 (0.50) L3MBTL1LMNARAB9ATSHRHTT
SCHEMBL17068997 0.78 L3MBTL1 (0.62) L3MBTL1CA1CA2PLK1CA12
SCHEMBL16481944 0.78 L3MBTL1 (0.62) L3MBTL1CA1CA2PLK1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2781512-B1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF UNIV SHANGHAI JIAOTONG (CN) 2017-06-28 EP disclosed
US-9145405-B2 Oxadiazole compound and preparation method thereof, pharmaceutical composition and use thereof SHANGHAI JIAO TONG UNIVERSITY (CN) 2015-09-29 US disclosed
US-9145405-B2 Oxadiazole compound and preparation method thereof, pharmaceutical composition and use thereof SHANGHAI JIAO TONG UNIVERSITY (CN) 2015-09-29 US disclosed
US-20140350026-A1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2014-11-27 US disclosed
US-20140350026-A1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2014-11-27 US disclosed
EP-2781512-A1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Jiao Tong University (CN) 2014-09-24 EP disclosed
US-5846986-A Therapeutic phenoxyalkylazoles and phenoxyalkylazines SANOFI (FR) 1998-12-08 US disclosed
US-5821257-A Thiadiazoles and their uses as antipicornaviral agents SANOFI (FR) 1998-10-13 US disclosed
US-5763461-A ANTIPICORNAVIRAL AGENTS SANOFI (FR) 1998-06-09 US disclosed
US-5750527-A VIRICIDES SANOFI (FR) 1998-05-12 US disclosed
US-5721261-A TREATING PICORNAVIRUS INFECTIONS SANOFI PHARMACEUTICALS, INC. (US) 1998-02-24 US disclosed
US-5650419-A Thiadiazoles and their use as antipicornaviral agents SANOFI, S.A. 1997-07-22 US disclosed
US-5618821-A VIRICIDES, PICORNAVIRUS SANOFI, S.A. (FR) 1997-04-08 US disclosed
US-5567719-A Thiadiazoles and their use as antipicornaviral agents STERLING WINTHROP, INC. (US) 1996-10-22 US disclosed
US-5552420-A TREATING PICORNAVIRAL INFECTIONS STERLING WINTHROP INC. (US) 1996-09-03 US disclosed
WO-1995031438-A1 THERAPEUTIC PHENOXYALKYLHETEROCYCLES SANOFI WINTHROP, INC. (US) 1995-11-23 WO disclosed
WO-1995031452-A1 THERAPEUTIC PHENOXYALKYLAZOLES AND PHENOXYALKYLAZINES SANOFI WINTHROP, INC. (US) 1995-11-23 WO disclosed
US-5453433-A Viricides; antiseptics to decontaminate polio, rhino and coxsackie viruses STERLING WINTHROP INC. (US) 1995-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350026-A1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF OXA1L, GTF3C3, CCR3 L3MBTL1 4191/4885CA1 1002/4885CA2 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.